Hemorrhagic Effects of Oral Anticoagulants: a Comparative Study Between Vitamin K Antagonists (VKA) and Direct Oral Anticoagulants (DOA)

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2015 Jul 22

PMID 26195273

Citations 1

Authors

J L Montastruc

V Rousseau

L Chebane

D Abadie

E Bondon-Guitton

G Durrieu

F Montastruc

H Bagheri

Affiliations

Soon will be listed here.

Citing Articles

Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.

Lafarge L, Khayi F, Bel-Kamel A, Charhon N, Sarfati L, Falquet B Drugs Aging. 2018; 35(6):569-574.

PMID: 29882202 DOI: 10.1007/s40266-018-0551-5.

References

Hernandez I, Baik S, Pinera A, Zhang Y . Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2014; 175(1):18-24. PMC: 6608584. DOI: 10.1001/jamainternmed.2014.5398. View

Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D . Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2012; 69(2):237-44. DOI: 10.1007/s00228-012-1321-7. View

Begaud B, Martin K, Haramburu F, Moore N . Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002; 288(13):1588. DOI: 10.1001/jama.288.13.1588. View

Graham D, Reichman M, Wernecke M, Zhang R, Southworth M, Levenson M . Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2014; 131(2):157-64. DOI: 10.1161/CIRCULATIONAHA.114.012061. View

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H . The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol. 2011; 68(5):767-75. DOI: 10.1007/s00228-011-1156-7. View

Southworth M, Reichman M, Unger E . Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368(14):1272-4. DOI: 10.1056/NEJMp1302834. View

Pierfitte C, Begaud B, Lagnaoui R, Moore N . Is reporting rate a good predictor of risks associated with drugs?. Br J Clin Pharmacol. 1999; 47(3):329-31. PMC: 2014220. DOI: 10.1046/j.1365-2125.1999.00881.x. View

Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2013; 383(9921):955-62. DOI: 10.1016/S0140-6736(13)62343-0. View

10.

Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N . Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2003; 57(1):86-92. PMC: 1884419. DOI: 10.1046/j.1365-2125.2003.01953.x. View

11.

Ollier E, Delavenne X . [Direct oral anticoagulant, useful pharmacological characteristics in clinical practice]. Therapie. 2014; 70(3):243-9. DOI: 10.2515/therapie/2014206. View